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THE IN VITRO SENSITIVITY OF BLASTOMYCES DERMATITIDLS
TO SIX DIAMIDINE DERIVATIVES*1
SHIRLEY McMILLEN, M. A., DANIEL S. KUSHNER, M. D. AND I. SNAPPER, M. D4
Demonstration of the fungistatic activity and therapeutic efficacy of stilbami-
dine and 2-hydroxystilbamidine against Blastomyces dermatitidis in vitro and in
vivo prompted an appraisal of the in vitro activity of other diamidine compounds.
The objectives of this study were (1) to develop a reproducible in vitro technic
for testing the drug sensitivity of fungi; (2) to investigate the mycelial and yeast
phase sensitivities of the organisms simultaneously, under conditions as similar
as possible; (3) to compare the fungistatic activity of the available diamidine
compounds; and, (4) to compare the activity of all drugs employed against a
number of strains of B. dermatitidis to determine the extent of strain variation
in sensitivity.
To fulfill these aims the described technic has been used to evaluate the ac-
tivity of 6 diamidine drugs against 12 isolates of B. dermatitidis.
EXPERIMENTAL METHOD
Medium: The performance of yeast phase sensitivity tests requires a medium
which will support yeast phase growth without the addition of substances which
antagonize the activity of the drugs employed. Brain-heart infusion blood me-
dium, which permits perpetuation of yeast phase cultures of blastomyces, con-
tains substances (probably nucleic acids) which neutralize the fungistatic ac-
tivity of the diamidine derivatives. While the organism cannot be maintained in
yeast phase through repeated transfers upon Sabouraud's agar, B. dermatitidis
will grow in acceptable yeast phase on that medium at 37° C. for a single transfer.
Duplicate sets of tests on the one medium, Sabouraud's dextrose agar, yielded
consistent and reproducible sensitivity levels with both mycelial and yeast
phases, with temperature of incubation as the only variable.
pH: An influence of pH upon drug activity as reported by Elson (1) was not
found to occur in the present study. Growth and sensitivity levels of B. derma-
titidis on Sabouraud's dextrose agar were comparable at pH 5.5 and p11 7.0.
Drugs: All drug solutions were freshly prepared in warm (37 C) sterile dis-
tilled water. The dilutions were used without sterilization since the diamidine
drugs are altered by heat and adsorbed to ifiter paper. (Henry and Grindly, cited
by Schoenbach and Greenspan) (2). The bacteriostatic properties of the drugs
prevented bacterial contamination. Trial experiments demonstrated that 100
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g/ml prevented and 1ig/ml permitted growth of B. dermatitidis in mycelial
phase, thus determining the range of dilution.
Inoculum: Yeast phase inoculum, maintained on brain-heart infusion blood
agar, was used throughout because it was easily prepared, it could be evenly dis-
tributed on the medium and it converted spontaneously to mycelial phase at
room temperature. The success and reproducibility of the fungistatic activity of
diamidine compounds against yeast phase of B. dermatitidis on Sarbouraud's
dextrose agar, however, was found to be dependent upon maintenance of the
370 C. temperature and the smoothness of the yeast phase inoculum. Cultures
required transfer at 2—3 day intervals on brain-heart infusion blood medium.
Homogeneity of the organism suspension was used as the criterion for the
smooth character of the culture, usually achieved after 4 to 7 transfers. Suspen-
sions of the yeast phase organisms were made in sterile saline warmed to 37° C.
and standardized approximately to barium sulfate turbidity standard 5. The
suspensions of yeast phase organisms were kept at 37° C. and inoculations were
completed within a 30 minute period. Much longer delay at any temperature, as
would be necessary for more exact standardization, resulted in rapid reversion
of the organism to mycelial phase, introducing considerable variation in control
growth and drug sensitivity.
The agar slants were inoculated by swabbing the surface with an ordinary
sterile cotton swab dipped into the suspension. This avoided the uneven dis-
tribution of particulate inoculum which resulted from ioop, pipette or needle
transfer.
Temperature: Incubation temperature proved to be a critical factor for both
mycelial and yeast phase testing. At usual room temperature of 20—25° C. the
results with myceial growth were reproducible, but at summer laboratory tem-
peratures of 22—37° C. the results were erratic. A stable 370 C. incubator gave uni-
form yeast phase results.
Time: Diamidine compounds are known to be unstable in solution. Solutions
of the described concentrations in non-inoculated broth medium of 4 of the stil-
bamidine derivatives studied were allowed to stand in the dark. At intervals of
0, 3, 7 and 10 days, 3 sets of these solutions were inoculated with different blasto-
myces strains. These assays showed that stilbamidine retained fungistatic ac-
tivity in broth medium for 16—18 days, 2-hydroxystilbamidine for 12—14 days,
aminostilbamidine for only 10 days and propamidine for 14 days. Sensitivity
levels were therefore read within 10 days after preparation of the drug-containing
medium.
Interpretation: Interpretation was made on a rigid standard which defined
inhibition as prevention of true mycelial growth in the drug-containing medium
at room temperature, and of yeast phase growth at 37°C. Thus, no attempt was
made to quantitate the partial inhibition observed with all of the diamidine
drugs at lesser concentrations (as low as 1g/m1). In doubtful cases, the pres-
ence of mycelia in the room temperature tests was determined by microscopic
examination of the tubes under low power.
Procedure: The drugs, in concentrations adjusted so that at least one tube
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showed growth within 24 hours of that in the control tube, were added to steri-
lized Sabouraud's dextrose agar slants in duplicate. Dilutions were calculated to
produce final concentrations of 100, 50, 25, 10, 5 and 1/Lg/ml, in 10 ml agar
slants. Suspensions of yeast phase B. dermatitidis cultures, 4 days old, were in-
oculated on the slants by swab. The inoculum was sufficient to ensure good con-
trol growth in not more than 5 days. One set of tubes was incubated at room
temperature (20—25° C.) and the duplicate at 37° C. The reading of cultures
was begun when the control tubes showed growth and was continued every 24
or 48 hours for 10 days, with time reckoned from the date of drug-medium prep-
aration, not from the appearance of growth. Growth was recorded as positive only
when true mycelial or yeast phase proliferation was apparent.
For each test run, the medium (with varying drug concentrations) was pre-
pared at the same time, and each tube was inoculated from the same suspension,
with the same swab and within the same time limits. A complete set of controls
was included in each experiment because of the great variability encountered in
the growth rate and cultural characteristics of various strains of B. dermatitidis.
EXPERIMENTAL MATERIALS
The drugs utilized in this study were:
All drugs were generously supplied by the William S. Merrell Company.
Stilbamidine isethionate 4,4' stilbenedicarboxamidine isethionate
2-hydroxystilbamidine 2-hydroxy 4,4' stilbenedicarboxamidine di- ($-hydroxy-
ethane sulfonate)
2-aminostilbamidine 2-amino 4,4' stilbenedicarboxamidine di- (f3-hydroxy-
ethane sulfonate)
Propamidine p, p' (trimethylenedioxy) dibenzamidine
Dibromopropamidine 2,2' dibromo 4,4' diamidinodiphenoxy propane di-(-hy-
droxyethane sulfonate)
Pentamidine p, p' (pentamethylenedioxy)dibenzamidine
The origin of the isolates of Blastomyces dermatitidis employed as test organ-
isms is shown in Table I.
RESULTS
The results tabulated in this study were obtained by replication of the pro-
cedure using freshly prepared inoculum, medium and drugs for each run to estab-
lish the reproducibility of the technic. Each test was performed 3 times and all
those which gave varying sensitivity levels in those trials were then repeated
until a stable endpoint was reached.
Table I records the inhibition levels of each drug against 12 isolates of B.
dermatitidis. It will be noted that no variation in sensitivity which could be re-
lated to the age of a culture on medium, to storage under oil or to previous
2-hydroxystilbamidine therapy was demonstrated. The yeast phase of the organ-
ism consistently showed greater sensitivity and much less strain variation of
sensitivity to the different drugs than did the mycelial phase.
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TABLE I
Sensitivity levels* of 1P4 isolates of B. dermatitidis at room temperature and 87°C. to 6
diamidine drugs
Isolate Source
Stilbami-
dine
R° 37°
2-hydroxy-stiami-
R° 37°
Aminostil-
bainidine
R° 370
Pro am-
iJne
R° 370
Dibromo-
proparni-
R° 37°
Pentami-
dine
R° 370
B-i. U. of Iii., 1952
B-2. ATCC 10225, 1947
B-3. VanSickle, 1952
B-4. Duke Univ., 1946
B-5. Liddell, 1952
B-6. Demerse, 1952
B-7a. Betts, 1952t
B-7b. Betts, 1952
B-8. Avant, 1953
B-9. N. Y. Skin & Cancer
Unit, 19531f
B-b. Alexander, 1953
B-il. King, 1953
50
25
50
50
50
50
50
50
25
50
10
50
25
5
5
25
25
50
25
5
10
5
5
5
50
50
100
100
100
100
50
50
50
50
100
50
5
5
5
25
25
50
5
5
50
5
5
5
25
10
25
25
25
50
50
25
25
25
50
25
5
5
5
10
5
10
5
5
5
5
5
1
50
50
50
50
50
100
50
100
50
25
25
50
5
5
5
10
25
25
10
5
10
5
5
5
—4
—
—
—
100
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
100
—
100
100
—
—
100
—
—
100
50
50
—
50
—
—
—
50
—
—
50
* sg/ml which inhibited growth.
t No inhibition at concentration of 100/jig/cc, at 25° and 50/jig/cc. at 37°.
Isolate obtained before 2-hydroxystilbamidine therapy.
§ Isolate obtained following relapse in same patient.¶ Isolate stored under oil with acquired pigment production.
The comparative fungistatic activity of the 6 drugs against the 12 isolates of
B. dermatitidi& is shown in Figure 1. The greater activity of the drugs at 370 C.
against the yeast phase of the organism grown on Sabouraud's medium is clearly
demonstrated. It is apparent from Figure 1 that of the four active drugs, amino-
stilbamidine was the most effective against both mycelial and yeast phases of
B. dermatitidis. However, the range of sensitivity of all strains to stilbamidine,
2-hydroxystilbamidine, and propamidine, was comparable to that obtained with
aminostilbamidine. Dibromopropamidine and pentamidine proved to be rela-
tivelyinactive against the strains tested in the trial run and were therefore omit-
ted from further study. If results are expressed in terms of inhibition of 50% of
strains tested (as in Table II), all 4 effective drugs caused inhibition of the
mycelial phase at 50g/ml (aminostilbamidine at 25jg/ml) and of the yeast
phase at 5tg/m1.
DISCUSSION
The active search for chemical analogues of compounds possessing fungistatic
properties requires the development of reproducible technics for evaluation of their
in vitro activity. Moreover, as the clinical efficacy of a number of such drugs be-
comes established, it is possible that such in vitro technics may aid in solving
specific therapeutic problems.
A comparison of the results presented here with those of other investigators
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TABLE II
Comparative in vitro sensitivities of B. dermatitidis to diamidine drugs*
Stilbamidine 2-hydroxy.stilbamidine
Aminostil-
bamidine Propamidine Pentamidine
R° 37° R° 37° R° 37° R° 37° R° 37°
Authorsf 50 5 50 5 25 5 50 5 100+ 50+
Bocobo4 et al... 100—1000 10—100 100 10 1000 1000
Christison & Co-
nant, 1953 25 200
Curtis & Harrell,
1952 10 10
Elson, 1945 3.75
Fahlberg, 1953.... 10 100 100
Snapper, et al,
1952 & 1953 3—750 1 3—750 4
Solotorovsky et
al., 1954 <2.5 <2.5 2.5 25
* All drug concentrations quoted have been converted to eg/ml.
t The concentration given is that at which growth of 50% or more of 12 strains tested
was completely inhibited.
Ranges represent results obtained with 3 isolates of B. dermatitidis.
§ Ranges represent results obtained with 4 isolates of B. dermatitidis.
of drug-instability in solution; and avoidance of Seitz filtration or heat steriliza-
tion of drug solutions. Thus may the discrepancy be explained between the wide
range of strain variation reported by others, and the relatively narrow range,
one to five fold, reported here (Table II).
The oldest derivative (propamidine) and the newest (aminostilbamidine) both
showed in vitro fungistatic activity equal to or slightly better than that of stil-
bamidine and 2-hydroxystilbamidine. It must be emphasized that clinical ap-
plication of propamidine has been discouraged by its reported toxicity. Amino-
stilbaniidine, an intensely orange compound, is deposited in the skin, causing
yellow discoloration if doses exceeding 2 gm are administered.
The apparent considerable increase in sensitivity of yeast phase organisms at
370 C. indicates the need for further investigation into the diphasic properties
of such organisms.
SUMMARY
A method is presented for determining reproducible in vitro myceial and yeast
phase sensitivity levels of Blastomyces dermatitidis to the diamidine drugs. The
fungistatic action of all drugs tested was more marked against the yeast forms
of blastomyces grown on Sabouraud's medium at 370C. than against the mycelial
forms grown at room temperature. Aminostilbamidine showed the greatest in-
hibition; the fungistatic activities of stilbamidine, 2-hydroxystilbamidine and
propamidine were about equal. Dibromopropamidine and pentamidine were in-
active. No significant strain variation was encountered.
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